Eli Lilly's Latest Obesity Drug Delivers Strong Results. It Might Work Too Well.

Core Viewpoint - The company reported that some patients discontinued participation in the trial due to concerns about excessive weight loss [1] Group 1 - The trial faced challenges as patient dropout rates increased [1]